We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
151
CALL
Arrowhead Research
ARWR
$12.2B
$1.01M 0.04%
708
-319
-31% -$4.18K
CPXX
152
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$1.01M 0.04%
341,624
-284,453
-45% -$783K
BCRX icon
153
BioCryst Pharmaceuticals
BCRX
$2.48B
$994K 0.04%
+77,987
New +$759K
NPSP
154
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$993K 0.04%
+30,058
New +$868K
CERE
155
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$989K 0.04%
185,608
-26,355
-12% -$138K
AMRN
156
CALL
Amarin Corp
AMRN
$298M
$950K 0.04%
270
+260
+2,600% +$8.15K
NBSE
157
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$940K 0.04%
+247
New +$930K
ALXA
158
CALL
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$932K 0.04%
2,040
– –
EXEL icon
159
PUT
Exelixis
EXEL
$14.2B
$890K 0.04%
2,625
+1,409
+116% +$4.87K
TBRA
160
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$889K 0.04%
+14,556
New +$885K
INSM icon
161
CALL
Insmed
INSM
$22.9B
$873K 0.04%
438
-864
-66% -$12.8K
OREX
162
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$865K 0.04%
140
+2
+1% +$116
CLVS
163
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$853K 0.04%
206
-794
-79% -$40.9K
CLVS
164
DELISTED
Clovis Oncology, Inc.
CLVS
$828K 0.04%
+20,000
New +$1.03M
RXII
165
DELISTED
GALENA BIOPHARMA INC COM
RXII
$812K 0.03%
265,350
-442,739
-63% -$1.35M
ARIA
166
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$808K 0.03%
+126,884
New +$873K
SGEN
167
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$807K 0.03%
211
-3,500
-94% -$132K
VVUS
168
CALL
DELISTED
Vivus Inc
VVUS
$795K 0.03%
+150
New +$7.71K
ALTO icon
169
PUT
Alto Ingredients
ALTO
$346M
$783K 0.03%
512
– –
ASRT
170
CALL
DELISTED
Assertio
ASRT
$766K 0.03%
9
– –
ECYT
171
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
$764K 0.03%
1,160
+1,006
+653% +$11.3K
ALNY icon
172
Alnylam Pharmaceuticals
ALNY
$38.8B
$758K 0.03%
+12,000
New +$713K
VIRX
173
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$752K 0.03%
5
+1
+25% +$1.16K
NBSE
174
CALL
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$745K 0.03%
+2
New +$7.53K
ARNA
175
DELISTED
Arena Pharmaceuticals Inc
ARNA
$690K 0.03%
11,782
-9,788
-45% -$616K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.